Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Alzheimer's Disease

Alzheimer's Disease

Recruiting

Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND)

The CCNA COMPASS-ND study aims to investigate the bases, commonalities, and distinguishing characteristics of Alzheimer disease and related neurodegenerative disorders. 

Recruitment Poster

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Dementia
Area
Vancouver
Age
50-85

MINT-01 (A Medium Chain Triglyceride INTervention for Alzheimer Disease (A MINT for AD Study)

This study will test the safety and tolerability of a medium chain triglyceride (MCT) supplement in those with Alzheimer Disease (AD). 

Recruitment Poster

Status
Recruiting
Principal Investigator
Haakon Nygaard
Body Locations and Systems
Alzheimer's Disease
Area
Vancouver
Age
50-90

Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)

The purpose of this project is to conduct a proof of concept study in patients with probable Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker compared to an Angiotensin Converting Enzyme inhibitor (ACEI).

recruitment poster

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
High Blood Pressure
Alzheimer's Disease
Area
Vancouver
Age
50 and above

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have, or are at risk of having an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.
This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).

 

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Neurologic Diseases
Dementia
Area
Vancouver
Age
18-80

Closed for Recruitment

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD.

Status
Closed for Recruitment
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Area
Vancouver
Age
50-85

Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.

Status
Closed for Recruitment
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Dementia
Area
Vancouver

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models.

Status
Closed for Recruitment
Principal Investigator
Haakon Nygaard
Body Locations and Systems
Alzheimer's Disease
Area
Vancouver
Age
55-85

Characterization of Dementia Due to Mixed Alzheimer and Subcortical Vascular Pathology

The purpose of this study is to determine the clinical, cognitive, motor, brain imaging, genetic and biochemical biomarker characteristics of Alzheimer disease (AD), subcortical vascular disease (SVaD) and mixed dementia (AD + sVaD).

Status
Closed for Recruitment
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Dementia
Area
Vancouver
Subscribe to Alzheimer's Disease

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy